Armistice Capital, LLC Travere Therapeutics, Inc. Transaction History

Armistice Capital, LLC

$5.71 Billion
Q2 2025

A detailed history of Armistice Capital, LLC transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Armistice Capital, LLC holds 8,876,000 shares of TVTX stock, worth $204 Million. This represents 2.3% of its overall portfolio holdings.

Number of Shares

8,876,000

Previous 8,872,000 0.05%

Holding current value

$204 Million

Previous $159 Million 17.37%

% of portfolio

2.3%

Previous 2.42%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$13.49 - $21.54 $53,960 - $86,160	4,000 Added 0.05%	8,876,000 $131 Million
Q1 2025 May 15, 2025	BUY	$17.07 - $23.75 $25.8 Million - $36 Million	1,514,000 Added 20.58%	8,872,000 $159 Million
Q4 2024 Feb 14, 2025	SELL	$13.65 - $19.85 $3.96 Million - $5.76 Million	-290,000 Reduced 3.79%	7,358,000 $128 Million
Q3 2024 Nov 14, 2024	BUY	$7.89 - $15.21 $1.17 Million - $2.25 Million	148,000 Added 1.97%	7,648,000 $107 Million
Q1 2024 May 15, 2024	BUY	$7.18 - $9.82 $832,880 - $1.14 Million	116,000 Added 1.57%	7,500,000 $57.8 Million
Q4 2023 Feb 13, 2024	SELL	$5.44 - $9.5 $631,040 - $1.1 Million	-116,000 Reduced 1.55%	7,384,000 $66.4 Million
Q3 2023 Nov 14, 2023	BUY	$7.64 - $17.25 $382,000 - $862,500	50,000 Added 0.67%	7,500,000 $67 Million
Q2 2023 Aug 14, 2023	BUY	$15.3 - $22.61 $4.62 Million - $6.83 Million	302,000 Added 4.22%	7,450,000 $114 Million
Q1 2023 May 15, 2023	BUY	$17.82 - $22.89 $13.1 Million - $16.8 Million	736,000 Added 11.48%	7,148,000 $161 Million
Q4 2022 Feb 14, 2023	BUY	$18.47 - $26.14 $10.6 Million - $15.1 Million	576,000 Added 9.87%	6,412,000 $135 Million
Q3 2022 Nov 14, 2022	BUY	$22.91 - $28.63 $11.8 Million - $14.8 Million	516,000 Added 9.7%	5,836,000 $144 Million
Q2 2022 Aug 15, 2022	BUY	$20.94 - $30.01 $7.58 Million - $10.9 Million	362,000 Added 7.3%	5,320,000 $129 Million
Q1 2022 May 16, 2022	BUY	$23.61 - $30.6 $20.8 Million - $26.9 Million	880,000 Added 21.58%	4,958,000 $128 Million
Q4 2021 Feb 14, 2022	SELL	$24.34 - $31.17 $16.3 Million - $20.9 Million	-670,000 Reduced 14.11%	4,078,000 $127 Million
Q3 2021 Nov 15, 2021	SELL	$12.98 - $25.03 $13 Million - $25 Million	-1,000,000 Reduced 17.4%	4,748,000 $115 Million
Q2 2021 Aug 16, 2021	BUY	$14.11 - $26.4 $47.9 Million - $89.5 Million	3,392,000 Added 143.97%	5,748,000 $83.9 Million
Q1 2021 May 17, 2021	BUY	$23.37 - $31.77 $55.1 Million - $74.9 Million	2,356,000 New	2,356,000 $58.8 Million

Others Institutions Holding TVTX

# of Institutions

230

Shares Held

102M

Call Options Held

1.71M

Put Options Held

401K

View Full List

About Travere Therapeutics, Inc.

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.48B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

More about TVTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Armistice Capital, LLC with notifications on news.

Account

Armistice Capital, LLC Travere Therapeutics, Inc. Transaction History